000288539 001__ 288539
000288539 005__ 20241127133857.0
000288539 0247_ $$2doi$$a10.1007/s00520-024-08373-x
000288539 0247_ $$2pmid$$apmid:38386101
000288539 0247_ $$2ISSN$$a0941-4355
000288539 0247_ $$2ISSN$$a1433-7339
000288539 037__ $$aDKFZ-2024-00403
000288539 041__ $$aEnglish
000288539 082__ $$a610
000288539 1001_ $$00000-0002-3136-3109$$aWang, Yan$$b0
000288539 245__ $$aPatient-reported symptom monitoring: using (big) data to improve supportive care at the macro-, meso-, and micro-levels.
000288539 260__ $$aNew York,NY$$bSpringer$$c2024
000288539 3367_ $$2DRIVER$$aarticle
000288539 3367_ $$2DataCite$$aOutput Types/Journal article
000288539 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1708700049_2947
000288539 3367_ $$2BibTeX$$aARTICLE
000288539 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000288539 3367_ $$00$$2EndNote$$aJournal Article
000288539 520__ $$aThis paper aims to provide a comprehensive understanding of the need for continued development of symptom monitoring (SM) implementation, utilization, and data usage at the macro-, meso-, and micro-levels.Discussions from a patient-reported SM workshop at the MASCC/ISSO 2022 annual meeting were analyzed using a macro-meso-micro analytical framework of cancer care delivery. The workshop categories 'initiation and implementation, barriers to adoption and utilization, and data usage' were integrated for each level.At the macro-level, policy development could encourage data sharing and international collaboration, including the exchange of SM methods, supportive care models, and self-management modules. At the meso-level, institutions should adjust clinical workflow and service delivery and promote a thorough technical and clinical integration of SM. At the micro-level, SM should be individualized, with timely feedback for patients, and should foster trust and understanding of AI decision support tools amongst clinicians to improve supportive care.The workshop reached a consensus among international experts on providing guidance on SM implementation, utilization, and (big) data usage pathways in cancer survivors across the cancer continuum and on macro-meso-micro levels.
000288539 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000288539 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000288539 650_7 $$2Other$$aReal-world data
000288539 650_7 $$2Other$$aSupportive care
000288539 650_7 $$2Other$$aSymptom monitoring
000288539 650_2 $$2MeSH$$aHumans
000288539 650_2 $$2MeSH$$aCancer Survivors
000288539 650_2 $$2MeSH$$aCognition
000288539 650_2 $$2MeSH$$aConsensus
000288539 650_2 $$2MeSH$$aInformation Dissemination
000288539 650_2 $$2MeSH$$aPatient Reported Outcome Measures
000288539 7001_ $$00000-0002-7399-0194$$aAllsop, Matthew J$$b1
000288539 7001_ $$aEpstein, Joel B$$b2
000288539 7001_ $$00000-0002-0683-8715$$aHowell, Doris$$b3
000288539 7001_ $$00000-0001-7610-3653$$aRapoport, Bernardo L$$b4
000288539 7001_ $$00000-0001-9495-9543$$aSchofield, Penelope$$b5
000288539 7001_ $$00000-0002-5803-3230$$aVan Sebille, Ysabella$$b6
000288539 7001_ $$0P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aThong, Melissa$$b7$$udkfz
000288539 7001_ $$00000-0002-6083-730X$$aWalraven, Iris$$b8
000288539 7001_ $$00000-0002-0592-7820$$aRyan Wolf, Julie$$b9
000288539 7001_ $$00000-0002-7802-1034$$avan den Hurk, Corina J G$$b10
000288539 773__ $$0PERI:(DE-600)1463166-0$$a10.1007/s00520-024-08373-x$$gVol. 32, no. 3, p. 182$$n3$$p182$$tSupportive care in cancer$$v32$$x0941-4355$$y2024
000288539 8564_ $$uhttps://inrepo02.dkfz.de/record/288539/files/s00520-024-08373-x.pdf
000288539 8564_ $$uhttps://inrepo02.dkfz.de/record/288539/files/s00520-024-08373-x.pdf?subformat=pdfa$$xpdfa
000288539 909CO $$ooai:inrepo02.dkfz.de:288539$$pVDB
000288539 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000288539 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000288539 9141_ $$y2024
000288539 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000288539 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000288539 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000288539 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000288539 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000288539 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000288539 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000288539 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000288539 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000288539 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSUPPORT CARE CANCER : 2022$$d2023-10-21
000288539 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000288539 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000288539 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-21
000288539 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000288539 980__ $$ajournal
000288539 980__ $$aVDB
000288539 980__ $$aI:(DE-He78)C071-20160331
000288539 980__ $$aUNRESTRICTED